Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
1. ACRS to present Phase 2a trial data for ATI-2138 on September 18. 2. ATI-2138 targets ITK and JAK3 for treating atopic dermatitis. 3. Efficacy results in preclinical studies support ATI-2138's potential. 4. Presentation at EADV could enhance visibility and investor interest. 5. ACRS aims to address unmet needs in immuno-inflammatory diseases.